Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Colon cancer tumor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
InactiveUS20060127402A1Accurate stagingReduce intrusionCompound screeningImpression capsAbnormal tissue growthLymphatic Spread
Owner:TECHNION RES & DEV FOUND LTD
Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
InactiveUS7037667B1Microbiological testing/measurementBiological material analysisCell membraneTumor antigen
Owner:AGENSYS
Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
InactiveUS20100119515A1Accurate stagingReduce intrusionCompound screeningOrganic active ingredientsAbnormal tissue growthLymphatic Spread
Owner:TECHNION RES & DEV FOUND LTD
Hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit and preparation method and detection method thereof
The invention provides a hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit comprises an upper shell, a lower shell, an immunostrip, test paper and the like; a gold-labeled composite containing a hemoglobin monoclonal antibody, a hemoglobin-haptoglobin composite monoclonal antibody and a transferrin monoclonal antibody is scribed on a nitrocellulose membrane; 3 test lines, a quality control line (15) and a gold-labeled composite membrane scribing line (8) are arranged on the nitrocellulose membrane in parallel. The invention further provides a preparation method and a detection method of the hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit. The hemoglobin, hemoglobin-haptoglobin composite and transferrin joint examination kit is convenient and simple in operation, stable in performance and accurate in result, has a relatively good reference value for early diagnosis and identification of colorectal cancer or colon cancer tumor or other tumors with lower gastrointestinal bleeding symptoms in clinic, significantly improves the positive detection rate of digestive hemorrhagic diseases, is suitable for clinical hospital examination and household self-examination, and provides measures for large-scale general examination of such diseases.
Owner:HANGZHOU HUIYUANTAI MEDICAL DEVICES
Norcantharidin monomer-acid monoester derivative and anti-tumor application thereof
The invention provides a norcantharidin monomer-acid monoester derivative and an application thereof. The structural formula of the derivative is shown as the No.3 formula (please see the specification), wherein R is selected from alkyl or benzyl of C1 to C3. An activity test proves that the third designed and synthesized norcantharidin monomer-acid monoester derivative has good inhabitation activity in liver cancer tumor cells, stomach cancer tumor cells and colon cancer tumor cells, and can be expected to be applied to preparing medicine for resisting the three tumors.
Owner:ZUNYI MEDICAL UNIVERSITY
Quantum dot targeting probe for colorectal cancer tumor tissue identification and preparation method thereof
InactiveCN102961761AThe synthesis method is simpleGood repeatabilityIn-vivo testing preparationsHybrid peptidesTumor tissueHistidine
The invention discloses a method for preparing a quantum dot targeting probe (TCP-1-H6) for colorectal cancer tumor tissue identification and belongs to the field of nano biotechnology. A novel polypeptide ligand comprises histidine sequences (1) for combining with quantum dots, a sequence (2) for providing a polypeptide rigidity structure and a targeting sequence (3), wherein various sequences are combined through peptide bonds. The bifunctional ligand is simple in synthesis method, the N end is combined with the quantum dots through six histidine sequences, the stability of the ligand and the quantum dots is greatly improved, and the polypeptide ligand can serve as a nano fluorescence probe to be applied to colorectal cancer tumor marking.
Owner:CHANGZHOU UNIV
Use of ursolic acid as colon tumor resistant medicament
InactiveCN101991579ABlock EGFR signaling pathwayOrganic active ingredientsAntineoplastic agentsSide effectApoptosis
The invention relates to use of ursolic acid as a colon tumor resistant medicament. The ursolic acid has the effects of inhibiting colon cancer / tumor cell proliferation and inducing apoptosis. In naked mouse in vivo experiments, the ursolic acid can effectively inhibit the proliferation of colon cancer transplanted tumor and inhibit the generation of tumor blood vessels, and has no obvious toxic or side effect on mice. The ursolic acid has the effect of inhibiting EGFR / MAPK signal channel phosphorylation of colon cancer cells, and the key target of the ursolic acid is to inhibit ERK1 / 2 protein phosphorylation. The ursolic acid which is synergetic with oxaliplatin serving as a clinical first-line chemotherapy medicament of the colon cancer has better curative effect. The ursolic acid has better proliferation inhibiting effect on the colon cancer cells of K-RAS gene mutation. The use of the ursolic acid as the colon tumor resistant medicament provides a new thought for treating the colon tumor.
Owner:ZHEJIANG UNIV
Application of polygonatum polysaccharide in preparation of drugs for assisting inhibition of colon cancer
ActiveCN104106763AHigh purityHigh activityNatural extract food ingredientsFood ingredient functionsBlood vesselPolygonatum
The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.
Owner:INFINITUS (CHINA) CO LTD
Recombinant mIL-22BP vector, and liposome complex and preparation methods and application thereof
InactiveCN110157733AImprove neutralizationBlock or reduce bindingPeptide/protein ingredientsMicroencapsulation basedTreatment fieldLiposome
The invention belongs to the field of tumor gene therapy, and specifically relates to a recombinant mouse mIL-22BP vector and preparation methods and application of a liposome complex thereof. The invention, in view of the problem that a liposome complex having the murine IL-22BP gene has not been reported so far, provides the recombinant murine IL-22BP vector and the liposome complex thereof. Thevector contains a gene encoding mouse IL-22BP protein and can be used for expressing mouse IL-22BP protein in eukaryotic cells; after vector is combined with a cationic liposome to form the complex,the complex can well play a role of resisting colon cancer tumor tissue growth, has a tumor growth resisting effect, can be used for preparing drugs for diagnosis or treatment of tumors, and providesa new choice for tumor treatment.
Owner:SICHUAN UNIV
Compositions and methods for selected tumour treatment
InactiveUS20050063995A1Reduce decreaseShorten the progressEnergy modified materialsColon cancer vaccineAbnormal tissue growthMelanoma
Disclosed are novel compositions, methods and vaccines, which upon administration to a patient suffering from a melanoma, colon carcinoma tumor or breast cancer, postpone and / or reduce the need for chemotherapy treatment, slow the progression of or eliminate the tumor and / or alleviate the symptoms of the tumor. The compositions comprise stressed colon carcinoma, melanoma or breast cancer cells, preferably autologous such cells.
Owner:VASOGEN IRELAND LTD
Quantum dot targeting probe kit for detecting tumor of colon cancer
The invention discloses a quantum dot targeting probe kit for detecting the tumor of colon cancer. The kit comprises (a) TCP-1-H6 polypeptide, (b) TP-1-H6 polypeptide, (c) water soluble quantum dots, (d) FITC, and (e) DAPI. Water soluble quantum dots and targeting TCP-1-H6 polypeptide are coupled through His-tag and taken as a fluorescence probe (TCP-1-H6-QD). TCP-1-H6-QD can specifically label the acceptor of colon 26 cell and tumor tissue slice of colon cancer, and will not recognize normal colon tissues and brain tissues. The provided kit has an important meaning for the diagnosis and treatment of color cancer.
Owner:CHANGZHOU UNIV
Application of rhizopus nigricans exopolysaccharides in preparation of medicine for treating or preventing gastrointestinal tumors
InactiveCN104042623AGrowth inhibitionImprove the quality of lifeOrganic active ingredientsAntineoplastic agentsRhizopusWilms' tumor
The invention relates to an application of rhizopus nigricans exopolysaccharides in preparation of a medicine for treating or preventing gastrointestinal tumors. The method for preparing the rhizopus nigricans exopolysaccharides comprises the following steps: (1) activating and performing fermental cultivation on rhizopus nigricans with a strain collection number of CGMCC NO.8436, and preparing fermentation liquor; (2) separating and purifying the fermentation liquor, and preparing a crude extracting solution; and (3) discoloring the crude extracting solution by resin columns, oscillating to remove proteins through a Seveage reagent, performing column chromatography purification on Sephadex G-50 sephadex, and preparing the rhizopus nigricans exopolysaccharides. An animal tumor model is established by utilizing the rhizopus nigricans exopolysaccharides, the tumor activity of an entity anti-alimentary system of the rhizopus nigricans exopolysaccharides is explored, the animal tumor experiment anti-tumor result proves that the rhizopus nigricans exopolysaccharides can obviously inhibit growth of tumor blocks of stomach cancer tumor mice and colon cancer tumor mice, and when the rhizopus nigricans exopolysaccharides are combined with modern chemotherapy drug cyclophosphamide, the anti-tumor curative effect is obviously higher than the anti-tumor effect of a single cyclophosphamide drug.
Owner:SHANDONG UNIV
Treatment and diagnosis of colon cancer
The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Owner:THE ROCKEFELLER UNIV
Application of humanized antibody for resisting 4-1BB
ActiveCN112794904AEnhance immune responseWide range of therapeutic usesAntipyreticAnalgesicsAutoimmune conditionAutoimmune disease
The invention discloses an application of a humanized antibody for resisting 4-1BB. The antibody can be used for detecting 4-1BB, blocking a 4-1BB / 4-1BBL signal channel, stimulating T cell activation, promoting T cell secretion of IFN-gamma, inhibiting colon cancer tumor and cell growth, and treating and / or preventing colon cancer. The HCDR1, the HCDR2 and the HCDR3 of the antibody are sequentially shown as the 31st site to the 35th site, the 50th site to the 64th site and the 98th site to the 106th site of SEQ ID No.1, and the LCDR1, the LCDR2 and the LHCDR3 are sequentially shown as the 24th site to the 34th site, the 50th site to the 56th site and the 89th site to the 97th site of SEQ ID No.2. The antibody provided by the invention has high affinity to human 4-1BB, can effectively enhance T cell response, can be used for regulating T cell and antibody mediated immune response, and can be used as an immunomodulator for treating cancers, autoimmune diseases, inflammatory diseases, infectious diseases and the like.
Owner:HEFEI HANKEMAB BIOTECH CO LTD
Method for synthesizing anticancer compound Na4Bi2Mn2W20C6H84N4O105
InactiveCN102351911AStrong proliferation inhibitory effectGood inhibition rateOrganic active ingredientsOrganic chemistryRoom temperaturePolyoxometalate I
The invention provides a method for synthesizing an anticancer compound Na4Bi2Mn2W20C6H84N4O105, which relates to a method for synthesizing an anticancer compound. The method comprises the following steps: 1, dissolving Na2WO4 under magnetic stirring in deionized water and heating, then regulating pH to obtain a solution A; 2, simultaneously adding MnCl2, solid imidazole and Bi(NO3)3 dissolved inHCl, uniformly mixing and heating to react, then cooling to the room temperature, filtering and standing. The synthesized Na4Bi2Mn2W20C6H84N4O105 is a polyoxometallate modified by active imidazole, has strong inhibition effect on tumor cells of human stomach, and has good inhibition rate on tumor cells of liver cancer and colorectal carcinoma.
Owner:HARBIN NORMAL UNIVERSITY
Application of 4-1H-1,2,3-triazole-beta-lactam derivative
InactiveCN102579468AImprove biological activityStrong proliferation inhibitory activitySilicon compound active ingredientsAntineoplastic agentsMedicineHuman glioma
The invention discloses the application of a 4-1H-1,2,3-triazole-beta-lactam derivative. The 4-1H-1,2,3-triazole-beta-lactam derivative is used for preparing a medicine for resisting human brain glioma and colon cancer. The 4-1H-1,2,3-triazole-beta-lactam derivative has better biological activity, and is proved to have stronger propagation inhibitory activity for the human brain glioma (U87mG) and colon cancer tumor (LS-174T) cells by in vitro activity test. Therefore, the 4-1H-1,2,3-triazole-beta-lactam derivative is a potential antitumor drug, and has the application of preparing antitumor pharmaceutical preparation.
Owner:ZHEJIANG UNIV
Application of Rhizoma Polygonatum Polysaccharide in the Preparation of Functional Foods with Auxiliary Inhibition of Colon Cancer
ActiveCN104106763BHigh purityHigh activityNatural extract food ingredientsFood ingredient functionsFiberBlood vessel
The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.
Owner:INFINITUS (CHINA) CO LTD
Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of medicament and kit
InactiveCN101676301AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenTumor cells
The invention provides a monoclonal antibody, which has the following characteristics: 1) the antibody is IgMs immunoglobulin and the light-chain type of the antibody is k-typed; (2) the antigen is identified into a sugar-chain structure with sialylation mucoprotein surface; the monoclonal antibody can specifically identify colorectal adenocarcinoma, endometrial adenocarcinoma and pancreatic carcinoma tissues, can not identify the corresponding normal tissues. Specifically, the monoclonal antibody is formed by the secreting of hybridomas cells with the accession number of CGMCC No. 2643, the amino acid sequence in the heavy-chain variable zone is shown as SEQ ID NO: 1, the amino acid sequence in the light-chain variable zone is shown as SEQ ID NO: 2. The invention also provides a use of the monoclonal antibody in the preparation of a medicament or a kit, wherein the medicament or the kit can be used for the screening of cancer, early-stage diagnosis, treatment monitoring and tumour imaging. In addition, the invention provides a new antibody for inhibitting the growth of the tumor cells of colorectal carcinoma.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of chemotherapeutic drug combined with trichoderma pseudokoningii exopolysaccharide in treating colon cancer
ActiveCN105412155AGrowth inhibitionProlong lifeOrganic active ingredientsFungi medical ingredientsWhite blood cellCD8
The invention discloses application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of a chemotherapeutic drug combined with the trichoderma pseudokoningii exopolysaccharide in treating the colon cancer. The trichoderma pseudokoningii exopolysaccharide (EPS) can significantly inhibit the growth of tumor masses in a mouse with the colon cancer, and can improve mouse immune organ index and the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum, increase the proportion of mouse cytotoxic T lymphocytes (CD8+T cells) in total T lymphocyte calculation and significantly activate mouse T lymphocytes and B lymphocytes; therefore, the EPS has an effect on treating the colon cancer; and the EPS, when taken for a preventive purpose, can also effectively improve the antitumor capacity of a body. In addition, the EPS, when combined with an existing chemotherapeutic drug, namely 5-fluorouracil (5-FU), is significantly better than the single medication of the 5-FU in antitumor effect. Moreover, the EPS can improve the life quality of the mouse with the colon cancer and can prolong the service life of the mouse.
Owner:WANNAN MEDICAL COLLEGE
Applications of human RRS1 gene and inhibitor
ActiveCN104774928AEnrich cancer treatment pathwaysOrganic active ingredientsGenetic material ingredientsHuman tumorColon cancer cell
The invention relates to the technical field of biology, and discloses the applications of human RRS1 gene in screening tumor treatment drugs and preparing tumor diagnosis / treatment drugs and an inhibitor. The human RRS1 gene is taken as the target, a proper target gene sequence is selected, and then an inhibitor is designed through a RNA interference mode, the inhibitor can efficiently inhibit the expression of RRS1 gene, and inhibit the nucleic acid molecules, recombinant carriers, slow viruses, which can promote the proliferation of human tumor cells especially colon cancer cells; the invention further provides applications of human RRS1 gene in screening tumor treatment drugs and preparing tumor diagnosis / treatment drugs, and the means for treating tumors are increased.
Owner:SHANGHAI JI KAI GENE TECH CO LTD
Dietary composition containing cistanche deserticola polysaccharide with inhibitory effects on colon cancer
ActiveUS20160227829A1High activityHigh purityOrganic active ingredientsFood preparationWilms' tumorBlood vessel
The present invention discloses the use of a Cistanche deserticola polysaccharide in the preparation of functional food having efficacy of supplementary for inhibiting colon cancer, wherein Cistanche deserticola polysaccharide is preferably prepared by the following method: with Cistanche deserticola as raw material, is prepared by the processes including extraction with boiling water, deproteinization, dialysis and ethanol treatment, the Cistanche deserticola polysaccharide has an effect of regulating tumor microenvironment, the Cistanche deserticola polysaccharide according to the present invention is able to regulate tumor microenvironment by many pathways of inhibiting tumor angiogenesis, immunosuppression, anti-oxidation and inhibiting the growth of colon cancer fibroblast etc., which demonstrate that it has good effect of supplementary for inhibiting colon cancer tumor.
Owner:INFINITUS (CHINA) CO LTD
Preparation method of colon cancer nuclear magnetic resonance multifunctional contrast agent
The invention discloses a preparation method of a colon cancer nuclear magnetic resonance multifunctional contrast agent. Colon cancer tumor targeting peptides (TCP-1) marked with dyes are combined with magnetic nanometer carriers; on one hand, the TCP-1 is specifically marked with the organic dyes Cy5.5, the N terminal is decorated with alkynyl, and then the TCP-1-Cy5.5 marked with alkynyl is synthesized; on the other hand, uniform ferric oxide nanometer particles (Azide-SPIO) decorated with azide are synthesized; finally, the multifunctional contrast agent (SPIO-TCP-1-Cy5.5) is prepared by coupling the TCP-1-Cy5.5 with the Azide-SPIO through click chemistry. The novel contrast agent for early diagnosis of colon cancer is developed, the nanometer particles are introduced to be specifically combined with and enter new blood vessel cells of tumor through the TCP-1, and the early tumor detection on the scale of few millimeters can be achieved by combining magnetic resonance imaging with far infrared fluorescence imaging.
Owner:CHANGZHOU UNIV
Application of polysaccharide of cistanche deserticola to preparation of functional foods with effects of assistance in inhibiting colon cancer
ActiveCN104116024AHigh purityHigh activityNatural extract food ingredientsFood ingredient functionsNeo angiogenesisPharmacology
The invention discloses an application of polysaccharide of cistanche deserticola to preparation of functional foods with effects of assistance in inhibiting colon cancer. Polysaccharide of cistanche deserticola is preferably prepared by adopting a preparation method comprising the following steps: with cistanche deserticola as a raw material, extracting with boiling water, and performing deproteinization, dialysis and ethanol treatment. Polysaccharide of cistanche deserticola has a function of regulating a tumor microenvironment. Polysaccharide of cistanche deserticola provided by the invention is capable of regulating the tumor microenvironment through multiple approaches of inhibiting tumor angiogenesis, suppressing the immunity, resisting oxidation and inhibiting the colon cancer fibroblast growth, and the like so as to indicate that polysaccharide of cistanche deserticola has a good function of assistance in inhibiting the colon cancer.
Owner:INFINITUS (CHINA) CO LTD
Application of aspirin in preventing or treating colon cancer
InactiveCN108853123AAbility to inhibit migrationAbility to inhibit invasionOrganic active ingredientsDigestive systemBiological regulationAspirin
The invention relates to application of aspirin in preventing or treating colon cancer and also relates to a medicinal composition containing the aspirin. The aspirin can relieve the decrease degree of platelet activation rate and inhibit the migration ability and invasion ability of tumor cells. The invention studies a biological regulation mechanism of the aspirin for the tumor microenvironmentof colon cancer and the medicinal effect on the colon cancer and provides a new idea for deep research and development of the aspirin and clinical treatment of the colon cancer.
Owner:苏斌斌
Docetaxel target prodrug and application thereof on preventing colorectal carcinoma
ActiveCN109420179AHas pharmacological research valueUse to cureOrganic active ingredientsPharmaceutical non-active ingredientsDiseaseCathepsin B
The invention belongs to the field of biomedicine, specifically relates to a docetaxel target prodrug and a pharmaceutical application thereof, and provides a novel docetaxel target prodrug represented by the formula (1) and an application thereof on preventing colorectal carcinoma. The provided compound has a pharmacology research value and can be used as an anti-cancer prodrug that targets the specific high expression of tumors of colorectal carcinoma. The prodrug can be used to treat colorectal carcinoma caused by specific high expression of one or more of matrix metalloproteinase MMP-7, cysteine cathepsin B, and fibroblast activator protein [alpha]. In the formula (1), A represents a substrate polypeptide sequence that can specifically identify and hydrolyze components that are obviously and highly expressed in tissues of colorectal carcinoma including but not limited to matrix metalloproteinase MMP-7, cysteine cathepsin B, and fibroblast activator protein [alpha]; B represents a degradable bridge connection group selected from (a to i) and is connected to the carbon end or nitrogen end of A through amido bonds; and R1 includes but not limited to a fluorine atom, a hydrogen atom, and the like.
Owner:FUDAN UNIV
Synthesis method and anti-tumor application of bisindole-pyridine derivatives
ActiveCN109160914AHas antitumor activityEnhanced inhibitory effectOrganic chemistryAntineoplastic agentsSynthesis methodsColon cancer cell
The invention relates to a simple preparation method and application of bisindole-pyridine derivatives. The simple preparation method and application of the bisindole-pyridine derivatives provided bythe invention has the advantages that on the basis of three-component reaction, methanol is used as a solvent under acid conditions for synthesis of the bisindole-pyridine derivatives through microwave-assisted reaction ring closing; and the bisindole-pyridine derivatives are antitumor-active, and particularly achieve strong inhabiting effects on HCT116 colon cancer cells.
Owner:CHONGQING UNIV OF ARTS & SCI
Application of Ganoderma lucidum spore powder polysaccharides to preparation of functional foodstuffs with auxiliary colon cancer inhibiting effect
InactiveCN110423284AHigh purityHigh activityAntinoxious agentsImmunological disordersWilms' tumorGanoderma lucidum
The invention discloses the application of Ganoderma lucidum spore powder polysaccharides to preparation of functional foodstuffs with auxiliary colon cancer inhibiting effect. The Ganoderma lucidum spore powder polysaccharides of the invention are prepared from Ganoderma lucidum spore powder through procedures including extraction with boiling water, deproteinization, dialysis and ethanol treatment. The Ganoderma lucidum spore powder polysaccharides have the function of regulating a tumor microenvironment. The ganoderma lucidum spore powder polysaccharides in the invention have high purity and activity, can regulate the tumor microenvironment by inhibiting tumor neovascularization and inhibiting the growth of colon cancer fibroblasts, and show good auxiliary colon cancer inhibiting effect. The preparation method for the Ganoderma lucidum spore powder polysaccharides in the invention is simple, stable and efficient in process, suitable for industrial production and low in cost.
Owner:ZHEJIANG WANSHOUKANG PHARMA CO LTD
Application of gastrodia tuber polysaccharide in preparation of functional food with effect of helping inhibit colon cancer
InactiveCN104116023AHigh purityHigh activityOrganic active ingredientsNatural extract food ingredientsNeo angiogenesisCancer research
The invention discloses application of gastrodia tuber polysaccharide in preparation of functional food with the effect of helping inhibit colon cancer. The gastrodia tuber polysaccharide is preferably prepared by the following method: extracting gastrodia tuber taken as a raw material with boiling water, removing protein, dialyzing and carrying out ethanol treatment. The gastrodia tuber polysaccharide has the function of adjusting the tumor microenvironment. The gastrodia tuber polysaccharide can adjust the tumor microenvironment through multiple ways such as inhabitation of tumor angiogenesis, activation of immunity and inhabitation of fibroblast growth of the colon cancer, so that the gastrodia tuber polysaccharide has a good effect of helping inhibit colon tumors.
Owner:INFINITUS (CHINA) CO LTD
Inhibition of macrophage migration inhibitory factor in melanoma and colon cancer
Compounds and compositions are provided which inhibit MIF. Methods of treatment of melanoma and colon cancers are also provided.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
The application of Trichoderma pseudoconii exopolysaccharide in the treatment and prevention of colon cancer, and its application in combination with chemotherapy drugs in the treatment of colon cancer
ActiveCN105412155BGrowth inhibitionProlong lifeOrganic active ingredientsFungi medical ingredientsWhite blood cellCD8
The invention discloses application of trichoderma pseudokoningii exopolysaccharide in preventing and treating colon cancer and application of a chemotherapeutic drug combined with the trichoderma pseudokoningii exopolysaccharide in treating the colon cancer. The trichoderma pseudokoningii exopolysaccharide (EPS) can significantly inhibit the growth of tumor masses in a mouse with the colon cancer, and can improve mouse immune organ index and the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in mouse serum, increase the proportion of mouse cytotoxic T lymphocytes (CD8+T cells) in total T lymphocyte calculation and significantly activate mouse T lymphocytes and B lymphocytes; therefore, the EPS has an effect on treating the colon cancer; and the EPS, when taken for a preventive purpose, can also effectively improve the antitumor capacity of a body. In addition, the EPS, when combined with an existing chemotherapeutic drug, namely 5-fluorouracil (5-FU), is significantly better than the single medication of the 5-FU in antitumor effect. Moreover, the EPS can improve the life quality of the mouse with the colon cancer and can prolong the service life of the mouse.
Owner:WANNAN MEDICAL COLLEGE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com